News | March 27, 2026
CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The Trust’s shift from single-use compostable cups to a reusable system was driven by the need to reduce environmental impact and control long-term costs
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Doctors at the hospital highlighted that robotic-assisted surgery enhances precision through superior 3D visualisation and improved instrument flexibility
Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
Subscribe To Our Newsletter & Stay Updated
